138 related articles for article (PubMed ID: 15791776)
1. [Therapeutic implications of ACE-gene polymorphism].
Dimopoulos-Xicki L; Haas M
Wien Med Wochenschr; 2005 Feb; 155(3-4):50-3. PubMed ID: 15791776
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients.
Kurland L; Melhus H; Karlsson J; Kahan T; Malmqvist K; Ohman KP; Nyström F; Hägg A; Lind L;
J Hypertens; 2001 Oct; 19(10):1783-7. PubMed ID: 11593098
[TBL] [Abstract][Full Text] [Related]
3. Beta blockers & left ventricular hypertrophy regression.
George T; Ajit MS; Abraham G
Indian Heart J; 2010; 62(2):139-42. PubMed ID: 21180305
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies.
Ruggenenti P; Bettinaglio P; Pinares F; Remuzzi G
Clin J Am Soc Nephrol; 2008 Sep; 3(5):1511-25. PubMed ID: 18550651
[TBL] [Abstract][Full Text] [Related]
5. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
[TBL] [Abstract][Full Text] [Related]
6. Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland.
Palmer AJ; Roze S; Valentine WJ; Ray JA; Frei A; Burnier M; Hess B; Spinas GA; Brändle M
Swiss Med Wkly; 2006 May; 136(21-22):346-52. PubMed ID: 16779715
[TBL] [Abstract][Full Text] [Related]
7. The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial.
Kurland L; Hallberg P; Melhus H; Liljedahl U; Hashemi N; Syvänen AC; Lind L; Kahan T
Am J Hypertens; 2008 Jul; 21(7):836-9. PubMed ID: 18464745
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis.
Hope S; Brecher P; Chobanian AV
Am J Hypertens; 1999 Jan; 12(1 Pt 1):28-34. PubMed ID: 10075381
[TBL] [Abstract][Full Text] [Related]
9. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
Zeller A; Battegay E
Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
[TBL] [Abstract][Full Text] [Related]
10. [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on Irbesartan or Irbesartan/HCTZ].
Schmieder RE; Krekler M
MMW Fortschr Med; 2005 Aug; 147(31-32):43. PubMed ID: 16128197
[No Abstract] [Full Text] [Related]
11. The value of irbesartan in the management of hypertension.
Bramlage P; Durand-Zaleski I; Desai N; Pirk O; Hacker C
Expert Opin Pharmacother; 2009 Aug; 10(11):1817-31. PubMed ID: 19601700
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
Kurland L; Melhus H; Karlsson J; Kahan T; Malmqvist K; Ohman P; Nyström F; Hägg A; Lind L
J Hypertens; 2002 Apr; 20(4):657-63. PubMed ID: 11910301
[TBL] [Abstract][Full Text] [Related]
13. Effects of lisinopril, irbesartan, and amlodipine on the thrombogenic variables in the early and late stages of the treatment in hypertensive patients.
Tiryaki O; Usalan C; Buyukhatipoglu H; Sayiner ZA; Kilisli H
Clin Exp Hypertens; 2012; 34(2):145-52. PubMed ID: 21967026
[TBL] [Abstract][Full Text] [Related]
14. A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension.
Lacourcière Y
Clin Ther; 2000 Oct; 22(10):1213-24. PubMed ID: 11110232
[TBL] [Abstract][Full Text] [Related]
15. [Microalbuminuria in patients with hypertension and cardiovascular comorbidity, REAL observational study of treatment with Irbesartan/HCTZ].
Tschöpe C; Tschöpe R; Unger T
MMW Fortschr Med; 2006 Jun; 148(25):48. PubMed ID: 16859162
[No Abstract] [Full Text] [Related]
16. [Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland].
Frei A; Palmer AJ; Burnier M; Hess B
Praxis (Bern 1994); 2006 Mar; 95(11):401-8. PubMed ID: 16570646
[TBL] [Abstract][Full Text] [Related]
17. [Clinical profiles of new angiotensin II receptor blockers: telmisartan, olmesartan medoxomil, and irbesartan].
Ishii M
Nihon Rinsho; 2004 Jan; 62(1):193-202. PubMed ID: 14737853
[TBL] [Abstract][Full Text] [Related]
18. Relationship between polymorphism of the angiotensin-converting enzyme gene and the response to angiotensin-converting enzyme inhibition in hypertensive patients.
Yu H; Zhang Y; Liu G
Hypertens Res; 2003 Nov; 26(11):881-6. PubMed ID: 14714579
[TBL] [Abstract][Full Text] [Related]
19. ACE Phenotyping as a Guide Toward Personalized Therapy With ACE Inhibitors.
Danilov SM; Tovsky SI; Schwartz DE; Dull RO
J Cardiovasc Pharmacol Ther; 2017 Jul; 22(4):374-386. PubMed ID: 28587581
[TBL] [Abstract][Full Text] [Related]
20. Clinical overview of irbesartan: expanding the therapeutic window in hypertension.
Man in't Veld AJ
J Hypertens Suppl; 1997 Dec; 15(7):S27-33. PubMed ID: 9532518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
